Crinetics Pharmaceuticals, Inc.(CRNX)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$33.53
- 52-Week Range
- $25.83 – $57.99
- YTD
- -28.25%
- IV Rank (30D)
- 14.42
- Straddle Price
- $5.25
- P/C Vol Ratio
- 0.92
- Market Cap
- $3.5B
Fair Value
-31.5% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.53% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 9.53% (VRP-adj) |
| WACC | 9.45% |
| Volatility Risk Premium | +2.9pp (IV − HV30), ERP adj -0bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +30.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.4B |
| Return on Equity (TTM) | -38.8% |
| Book / Price | 39.6% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 92.9% |
| FCF Margin (TTM) | -2321.7% |
| Debt / Equity | 0.00 |
| Quality Score | 3/6 — normal (10y DCF) |
| SMA 50 | $37.50 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $35.20 |
| Bollinger Width / SMA20 | 50.7% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $3B |
Peers used for multiples: JAZZ, OGN, RPRX
(filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$23.62
Current Price
$34.47
Deviation
-31.5%
Forward-Return Rank
SHORT
gates ✓
?
| Horizon | Expected α | z Pred | Blended z | Rank % | Active? |
|---|---|---|---|---|---|
| 21d | -6.1% | -0.98 | -0.74 | 39.8% | — |
| 42d | -7.7% | -0.75 | -0.74 | 39.8% | — |
| 63d | -8.5% | -0.70 | -0.74 | 39.8% | — |
Expected α = forward-return point estimate vs SPY (e.g., +7.5% means the predictor expects this stock to outperform SPY by 7.5% over that horizon).
For SHORT direction the model uses a different ranking metric (conviction-weighted deviation, not the LGBM prediction); Expected α is shown for reference.
⚠ flags rows where Expected α disagrees with the FV direction — two independent signals are in conflict; conviction is low even if rank looks extreme.
Forward-Return Rank. A proprietary ensemble of a machine-learning forward-return model and a conviction-weighted fundamental score, ranked cross-sectionally each day across the S&P 500 (and broader universes on the screener). Each stock is scored at three horizons (21/42/63 trading days). "Active" = top/bottom 5% AND all risk filters pass. Backtested mean alpha vs SPY on active picks: 21d LONG +13.4%, 63d +34.9% (S&P 500, walk-forward). Past performance is not indicative of future results.
Value vs momentum conflict ⚠. The "FV direction" (long/short) comes from the fundamentals-based engine — price vs intrinsic value. The "Expected α" comes from a separate machine-learning predictor trained on ~12 features (sector, options-implied move, beta, institutional flow, etc.). Sometimes the two disagree: a stock is overvalued by fundamentals but the predictor expects it to keep outperforming (sector or momentum tailwinds). When all 3 horizons disagree, treat the direction signal as low-conviction — neither model is strongly recommending a position.
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 29.2× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 12.0× · 3 peers |
| Peer P/B | $46.56 | 50% | median 3.5× · 3 peers |
| Peer P/S | $0.67 | 50% | median 3.2× · 3 peers |
| Market Anchor (SMA50) | $37.50 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-06-12 · updated 2026-06-12 20:59:55.687000
Info
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $3.5B
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH an…
Price History
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -6.23% | 6 |
| Feb | -2.61% | 6 |
| Mar | -2.20% | 6 |
| Apr | +0.73% | 6 |
| May | -2.36% | 6 |
| Jun | -3.65% | 6 |
| Jul | +3.12% | 5 |
| Aug | +6.42% | 5 |
| Sep | +17.58% | 5 |
| Oct | +4.04% | 5 |
| Nov | +4.20% | 5 |
| Dec | +3.16% | 5 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $35.01
SMA 50: $37.46
SMA 200: $41.65
Current: $34.47
EMA 12: $34.48
EMA 26: $35.54
MACD: -1.0625 | Signal: 0.0400
BEARISH
ADX (14): 14.44
RANGE
+DI: 21.50
−DI: 24.97
Momentum Oscillators
RSI (14): 45.49
NEUTRAL
Stoch %K: 33.98
Stoch %D: 35.15
Williams %R: -57.15
Volume & Volatility
BB Upper: $37.82
BB Lower: $32.20
NEUTRAL
OBV: 32,029
Vol SMA 20: 969,282
Vol ROC: -46.17%
ATR: $1.72
True Range: $1.70
HV 20: 51.4%
HV 30: 65.3%
HV 60: 55.3%
Data Summary
Data Points: 500
Last Updated: 2026-06-13T13:41:30.322000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.
Earnings History
7 of 8 under expected move
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-08-08 | After-Close | 9.07% | 4.26% | 0.47x | Within |
| 2024-11-12 | After-Close | 6.39% | 1.83% | 0.29x | Within |
| 2025-02-27 | After-Close | 12.87% | 8.04% | 0.62x | Within |
| 2025-05-08 | After-Close | 10.41% | 5.52% | 0.53x | Within |
| 2025-08-07 | After-Close | 8.12% | 4.11% | 0.51x | Within |
| 2025-11-06 | After-Close | 12.76% | 8.47% | 0.66x | Within |
| 2026-02-26 | After-Close | 14.58% | 5.88% | 0.40x | Within |
| 2026-05-07 | After-Close | 10.03% | 14.12% | 1.41x | Exceeded |
Options Activity
- IV Rank (30D)
- 14.42
- IV Rank (7D)
- 100
- Avg IV
- 70.2%
- Straddle (30D)
- $5.25
- Straddle (7D)
- $3.20
- P/C Volume
- 0.92
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Volatility Surface
Enter a ticker to render the implied volatility surface.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 1.12
- Correlation (SPY)
- 24.1%
- R²
- 0.06
- Ann. Volatility
- 57.4%
- SPY Volatility
- 12.3%
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
? 13F Guide
Diluted shares outstanding: 96,540,500 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
6 filers$2.55M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $1.18M | 46.37% | 2026-03-31 |
| 2 | CITADEL ADVISORS LLC Custodian | $653.76K | 25.60% | 2026-03-31 |
| 3 | JANE STREET GROUP, LLC Custodian | $468.53K | 18.35% | 2026-03-31 |
| 4 | SIMPLEX TRADING, LLC Custodian | $174.34K | 6.83% | 2026-03-31 |
| 5 | Walleye Capital LLC | $54.48K | 2.13% | 2026-03-31 |
| 6 | GROUP ONE TRADING LLC Custodian | $18.16K | 0.71% | 2026-03-31 |
5 filers$3.10M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $1.39M | 44.85% | 2026-03-31 |
| 2 | JANE STREET GROUP, LLC Custodian | $719.14K | 23.18% | 2026-03-31 |
| 3 | SIMPLEX TRADING, LLC Custodian | $395.89K | 12.76% | 2026-03-31 |
| 4 | CITADEL ADVISORS LLC Custodian | $370.46K | 11.94% | 2026-03-31 |
| 5 | IMC-Chicago, LLC Custodian | $225.18K | 7.26% | 2026-03-31 |
Insider Activity
Latest: 2026-06-02
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-02 | Richard Scott Struthers | President & CEO | Gift (G) | — | — | EDGAR | |
| 2026-04-10 | Jeff E. Knight | Chief Dev. & Operating Officer | Mixed | −6,729 | $31.63 | -$1.66M | EDGAR |
| 2026-03-18 | Stephen F. Betz | Chief Scientific Officer | Sell (S) | −10,612 | $37.37 | -$396.6K | EDGAR |
| 2026-03-18 | Jeff E. Knight | Chief Operating Officer | Sell (S) | −9,911 | $37.37 | -$370.4K | EDGAR |
| 2026-03-18 | Richard Scott Struthers | President & CEO | Sell (S) | −21,981 | $37.37 | -$821.5K | EDGAR |
| 2026-03-13 | Coelho Rogerio Vivaldi | Director | Sell (S) | −5,000 | $36.15 | -$180.8K | EDGAR |
| 2026-03-04 | Stephanie Okey | Director | Sell (S) | −3,000 | $39.67 | -$119.0K | EDGAR |
| 2026-03-04 | Tobin Schilke | Chief Financial Officer | Sell (S) | −6,713 | $39.67 | -$266.3K | EDGAR |
| 2026-02-25 | Isabel Kalofonos | Chief Commercial Officer | Award (A) | +34,000 | — | EDGAR | |
| 2026-02-25 | Stephen F. Betz | Chief Scientific Officer | Award (A) | +30,000 | — | EDGAR | |
| 2026-02-25 | Richard Scott Struthers | President & CEO | Award (A) | +62,000 | — | EDGAR | |
| 2026-02-25 | Jeff E. Knight | Chief Operating Officer | Award (A) | +34,000 | — | EDGAR | |
| 2026-02-25 | Tobin Schilke | Chief Financial Officer | Award (A) | +32,000 | — | EDGAR | |
| 2026-01-07 | Isabel Kalofonos | Chief Commercial Officer | Mixed | — | $47.80 | -$36.0K | EDGAR |
| 2025-12-29 | Stephen F. Betz | Chief Scientific Officer | Exer (M) | +18,000 | $1.91 | $34.4K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
29 insiders · @ $34.47
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | JOSEPH EDELMAN | 10%+ Owner | 5,321,032 | $183.42M | $96.78M | 3 | 2022-04-18 |
| 2 | PERCEPTIVE ADVISORS LLC | 10%+ Owner | 3,659,381 | $126.14M | $45.00M | 1 | 2020-04-20 |
| 3 | 5AM Partners IV, LLC | 10%+ Owner | 2,507,797 | $86.44M | -$10.80M | 2 | 2019-03-20 |
| 4 | Vivo Capital Fund VIII, L.P. | 10%+ Owner | 2,458,445 | $84.74M | -$12.68M | 1 | 2020-04-07 |
| 5 | PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | Director | 2,187,953 | $75.42M | $60.46M | 2 | 2018-08-27 |
| 6 | Richard Scott Struthers | President & CEO | 615,878 | $21.23M | -$23.12M | 35 | 2026-06-02 |
| 7 | Vivo Opportunity, LLC | 10%+ Owner | 376,785 | $12.99M | -$2.97M | 1 | 2020-01-31 |
| 8 | Vivo Opportunity Fund, L.P. | 10%+ Owner | 376,285 | $12.97M | -$1.53M | 1 | 2020-02-06 |
| 9 | Vivo Capital Surplus Fund VIII, L.P. | 10%+ Owner | 298,625 | $10.29M | $22.62M | 4 | 2020-04-17 |
| 10 | Vivo Capital VIII, LLC | 10%+ Owner | 210,373 | $7.25M | -$46.39M | 1 | 2019-03-25 |
| 11 | Jeff E. Knight | Chief Dev. & Operating Officer | 190,452 | $6.56M | -$7.04M | 16 | 2026-04-10 |
| 12 | Ajay Madan | Chief Development Officer | 185,995 | $6.41M | -$60.2K | 4 | 2022-03-02 |
| 13 | Stephen F. Betz | Chief Scientific Officer | 141,342 | $4.87M | -$8.75M | 56 | 2026-03-18 |
| 14 | Marc Wilson | CFO | 136,092 | $4.69M | -$6.64M | 15 | 2024-09-30 |
| 15 | 5AM Co-Investors IV, L.P. | 10%+ Owner | 129,483 | $4.46M | -$34.41M | 1 | 2019-01-24 |
| 16 | WENDALL WIERENGA | Director | 116,146 | $4.00M | $0 | 8 | 2025-06-13 |
| 17 | Andrew J. Schwab | 94,489 | $3.26M | -$33.30M | 1 | 2019-06-25 | |
| 18 | Tobin Schilke | Chief Financial Officer | 78,121 | $2.69M | -$266.3K | 3 | 2026-03-04 |
| 19 | Dana Pizzuti | Chief Med and Dev Officer | 66,837 | $2.30M | -$7.11M | 22 | 2025-12-03 |
| 20 | James Hassard | Chief Commercial Officer | 44,259 | $1.53M | -$1.33M | 6 | 2024-07-09 |
| 21 | Alan Seth Krasner | Chief Medical Officer | 43,210 | $1.49M | -$318.1K | 9 | 2023-10-19 |
| 22 | Isabel Kalofonos | Chief Commercial Officer | 34,834 | $1.20M | -$137.5K | 3 | 2026-02-25 |
| 23 | Matthew K Fust | Director | 22,836 | $787.2K | -$3.70M | 16 | 2025-09-30 |
| 24 | Coelho Rogerio Vivaldi | Director | 16,823 | $579.9K | -$70.5K | 8 | 2026-03-13 |
| 25 | Weston Nichols | Director | 16,300 | $561.9K | $0 | 7 | 2025-06-13 |
| 26 | Caren Deardorf | Director | 16,300 | $561.9K | $0 | 6 | 2025-06-13 |
| 27 | Camille L Bedrosian | Director | 16,300 | $561.9K | $0 | 6 | 2025-06-13 |
| 28 | Stephanie Okey | Director | 13,300 | $458.5K | -$930.7K | 9 | 2026-03-04 |
| 29 | 5AM Ventures IV, L.P. | 10%+ Owner | 1,723 | $59.4K | $0 | 1 | 2019-02-22 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 2.8 |
| P/S Ratio | 195.7 |
| EV/EBITDA | -6.3 |
| TTM Revenue | $0.0B |
| TTM Net Income | $-0.5B |
| TTM EPS | $-5.13 |
| ROE | -38.8% |